Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial.

@article{Tak2012SafetyAE,
  title={Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight–week randomized, double-blind, placebo-controlled, parallel-group phase III trial.},
  author={Paul Peter Tak and Philip J Mease and Mark C Genovese and Joel Kremer and Boulos Haraoui and Yoshiya Tanaka and Clifton O Bingham and Ali Ashrafzadeh and Helen Travers and S Safa-Leathers and Sudeep Kumar and Wolfgang Dummer},
  journal={Arthritis and rheumatism},
  year={2012},
  volume={64 2},
  pages={360-70}
}
OBJECTIVE To evaluate the safety and efficacy of ocrelizumab plus methotrexate (MTX) or leflunomide (LEF) in patients with active rheumatoid arthritis (RA) and an inadequate response to tumor necrosis factor α inhibitors. METHODS This was a multicenter randomized, double-blind, placebo-controlled, parallel-group study that continued over 48 weeks. Patients receiving stable doses of MTX or LEF were randomized to receive 2 infusions of placebo (n = 277), ocrelizumab 200 mg (n = 278), or… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…